Clinical trial · Interventional
ReIrradiation With FDG-PET Guided Dose Painting
ReIrradiation With FDG-PET Guided Dose Painting for Recurrent and Second Primary Head and Neck Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Dose-painting may increase the chance of cure at minimised radiation-induced toxicity in intensity-modulated radiotherapy (IMRT) for primary head and neck cancer. This could also apply for recurrent and second primary head and neck cancers in previously irradiated volumes. This trial (RIDPAINT) investigates the feasibility of FDG-PET guided radiotherapy using IMRT dose-painting by contours for patients with recurrent and second primary head and neck cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FDG-PET guided dose painting | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Number of participants accomplishing FDG-PET guided radiotherapy for recurrent and second primary head and neck cancer.
- timeFrame
- 1 month
Secondary outcomes (2)
- measure
- Locoregional control (at 6 months after inclusion) evaluated with PET/CT (according to RECIST).
- timeFrame
- 6 months
- measure
- Number of participants with adverse events.
- timeFrame
- 3 years
- description
- Number of participants with toxicity using CTCAE v3.0.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically verified invasive carcinoma of the head and neck region; ICD10: C01, C02.0 - C02.9; C03.0 - C03.9; C04.0 - C04.9; C05.0 - C05.9; C06.0 - C06.9; C09.0 - C09.9; C10.0 - C10.9; C11.0 - C11.9; C12; C13.0 - C13.9; C14.0 - C14.9; C30; C31.0 - C31.9; C32.0 - C32.9 * Planned treatment at the Norwegian Radium Hospital or at other participating university hospitals * Age ≥18 years * Ability to understand and respond to the questionnaires * Informed consent received * Squamous cell carcinoma in the head and neck region of patients previously irradiated for head and neck cancer * No grade 3 or more late toxicity (except xerostomia) after the initial radio(chemo)therapy * Minimal interval 12 months after the initial radio(chemo)therapy for primary head and neck cancer * ECOG performance status ≤ 2 Exclusion Criteria: * Patients planned for standard curative treatment (radical RT +/-concomitant chemotherapy or postoperative RT of primary disease) * Patients who previously have been re-irradiated for overlapping second primary or relapse * Other second primary tumors that are not under control * Distant metastatic disease
References
Publications (1)
- RESULTSkjotskift T, Evensen ME, Furre T, Moan JM, Amdal CD, Bogsrud TV, Malinen E, Dale E. Dose painting for re-irradiation of head and neck cancer. Acta Oncol. 2018 Dec;57(12):1693-1699. doi: 10.1080/0284186X.2018.1512753. Epub 2018 Oct 3. PMID 30280623